InsiderTrades.com logo

Joana Goncalves Biography and Net Worth

Chief Medical Officer of Oruka Therapeutics
  • LinkedIn
  • Phone
  • Email
  • Website


Dr Goncalves is our Chief Medical Officer.

She is a seasoned leader with more than 20 years’ experience in the biopharmaceutical industry. Prior to joining Oruka, Dr Goncalves served as the Chief Medical Officer at Cara Therapeutics from 2018 to 2024, where she led the development of oral difelikefalin in dermatological diseases associated with chronic itch and helped bring IV KORSUVA™ through a regulatory review and FDA approval. She has experience building and leading multi-functional, high-performing teams that have gotten new therapies approved and successfully launched. She was part of the core team at Celgene that developed and launched OTEZLA® (apremilast), the first oral drug for psoriasis. Earlier in her career, she held roles in clinical development, safety, and medical affairs at LEO Pharma and Novartis.

She trained as a physician at the University of Cape Town, South Africa, where she received her MBChB (Bachelor of Medicine and Bachelor of Surgery).

What is Joana Goncalves' net worth?

The estimated net worth of Joana Goncalves is at least $51.96 thousand as of January 15th, 2026. Dr. Goncalves owns 1,518 shares of Oruka Therapeutics stock worth more than $51,961 as of January 31st. This net worth estimate does not reflect any other investments that Dr. Goncalves may own. Learn More about Joana Goncalves' net worth.

How do I contact Joana Goncalves?

The corporate mailing address for Dr. Goncalves and other Oruka Therapeutics executives is 10170 CHURCH RANCH WAY SUITE 100, WESTMINSTER CO, 80021. Oruka Therapeutics can also be reached via phone at 720-940-2100 and via email at [email protected]. Learn More on Joana Goncalves' contact information.

Has Joana Goncalves been buying or selling shares of Oruka Therapeutics?

In the last ninety days, Joana Goncalves has sold $222,670.00 of Oruka Therapeutics stock. Most recently, Joana Goncalves sold 7,000 shares of the business's stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $31.81, for a transaction totalling $222,670.00. Following the completion of the sale, the insider now directly owns 1,518 shares of the company's stock, valued at $48,287.58. Learn More on Joana Goncalves' trading history.

Are insiders buying or selling shares of Oruka Therapeutics?

In the last year, Oruka Therapeutics insiders bought shares 3 times. They purchased a total of 98,339 shares worth more than $1,128,456.02. In the last year, insiders at the sold shares 2 times. They sold a total of 14,000 shares worth more than $436,940.00. The most recent insider tranaction occured on January, 15th when insider Joana Goncalves sold 7,000 shares worth more than $222,670.00. Insiders at Oruka Therapeutics own 24.7% of the company. Learn More about insider trades at Oruka Therapeutics.

Information on this page was last updated on 1/15/2026.

Joana Goncalves Insider Trading History at Oruka Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/15/2026Sell7,000$31.81$222,670.001,518View SEC Filing Icon  
12/19/2025Sell7,000$30.61$214,270.001,518View SEC Filing Icon  
See Full Table

Joana Goncalves Buying and Selling Activity at Oruka Therapeutics

This chart shows Joana Goncalves's buying and selling at Oruka Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Oruka Therapeutics Company Overview

Oruka Therapeutics logo
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Read More

Today's Range

Now: $34.23
Low: $32.93
High: $35.45

50 Day Range

MA: $30.93
Low: $26.40
High: $35.53

2 Week Range

Now: $34.23
Low: $5.49
High: $36.51

Volume

383,499 shs

Average Volume

502,870 shs

Market Capitalization

$1.66 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A